Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × tofacitinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Psoriasis 6 Lymphoma, Follicular 6 Bronchiolitis Obliterans Syndrome 6 Arthritis, Rheumatoid 5 Pruritus 4 Plaque, Amyloid 1 Myasthenia Gravis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Extranodal NK-T-Cell 1 Glioblastoma 1 Cholangiocarcinoma 1 Arthritis, Psoriatic 1 Adenocarcinoma 1

Interventions

Temozolomide 353 Radiotherapy 177 Bevacizumab 134 Radiation 68 Magnetic Resonance Spectroscopy 63 Lomustine 43 pembrolizumab 36 Surgical Procedures, Operative 35 Irinotecan 35 Carmustine 35 Nivolumab 26 Carboplatin 25 Radiosurgery 22 Specimen Handling 21 Erlotinib Hydrochloride 20 Chemotherapy, Adjuvant 20 Radiotherapy, Intensity-Modulated 18 Aminolevulinic Acid 18 Drug Therapy 17 Cyclophosphamide 16 sargramostim 15 O(6)-benzylguanine 13 Radiotherapy, Conformal 12 Granulocyte-Macrophage Colony-Stimulating Factor 12 Everolimus 12 Blood Specimen Collection 12 Vorinostat 11 Sunitinib 11 Cilengitide 11 temsirolimus 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05326464 2025-12-15

Tofacitinib in Recurrent GBM Patients

University of Texas Southwestern Medical Center

Phase 3 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡